Meeting highlights--International Consensus Panel on the treatment of primary breast cancer.
The 7th International Conference on Adjuvant Therapy of Primary Breast Cancer, with several thousand delegates from 70 countries, was held in February 2001 in St. Gallen, Switzerland. Its consensus recommendations were summarized in the Sept. 15 issue of the Journal of Clinical Oncology (Vol. 19, No. 18, 2001: pp 3817-3827). The panel conference developed guidelines advising that all patients with endocrine-responsive tumors receive anti-hormonal therapy, including those at minimal risk of recurrence (defined as a 10% risk at 10 years). The panel further lowered the threshold defining endocrine-responsive disease to tumors containing as few as 1% of cells that stain positive for steroid hormone receptors. Treatment of primary breast cancer should depend on the hormonal status of tumors. The last set of guidelines, issued in 1998, supported a more limited use of endocrine-based therapy, but recent research has convinced the oncology community otherwise. Postmenopausal women have the greatest prevalence of hormone-positive tumors, and more than one-third of breast cancers in women of child-bearing age are estrogen dependent. The panel also highlighted several other important advances, including: the importance of factoring patient preferences into treatment decisions; the value of sentinel lymph node biopsy in avoiding extensive surgery; and incorporation of new agents and improved outcome in the treatment of breast cancer.